• SynAct Pharma’s third-quarter 2026 loss after tax narrowed 10% year over year to SEK 32.18 million.
• Operating expenses fell 15% to SEK 30.09 million compared with the year-earlier quarter.
• Quarter-end cash and cash equivalents dropped 46% year over year to SEK 42.36 million.
• On October 27, SynAct signed its first commercial partnership for resomelagon with a leading Brazilian pharmaceutical company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynAct Pharma AB published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.